BioLineRx (BLRX) Revenue (2024 - 2025)
BioLineRx's (BLRX) quarterly Revenue came in at $194000.0 in Q4 2025, down 98.35% year-on-year from $11.7 million in Q4 2024, and down 54.57% quarter-over-quarter from $427000.0 in Q3 2025.
BioLineRx (BLRX) Revenue (2024 - 2025) Analysis & Trends
BioLineRx's Revenue history runs 2 years deep, the most recent figure standing at $194000.0 for Q4 2025.
- On a quarterly basis, Revenue fell 98.35% year-over-year to $194000.0 in Q4 2025; TTM through Dec 2025 was $1.2 million, a 95.92% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 95.92% from the prior year.
- Revenue eased to $194000.0 in Q4 2025 per BLRX's latest filing, from $427000.0 in the prior quarter.
- Across five years, Revenue topped out at $11.7 million in Q4 2024 and bottomed at $194000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | BioLineRx | 7.21 Bn | 7.21 Bn | 154,000.00 | 194,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | 6.86 Mn |